Drug profile · INN
oxybutynin chloride
OXYBUTYNIN CHLORIDE
oxybutynin chloride (OXYBUTYNIN CHLORIDE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: transdermal. Current US regulatory status: approved.
Drug details — oxybutynin chloride
- US status
- approved
- Class
- —
- Route
- TRANSDERMAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
oxybutynin chloride (OXYBUTYNIN CHLORIDE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: transdermal. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M3 antagonist
Primary target: Muscarinic acetylcholine receptor M2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is oxybutynin chloride?
oxybutynin chloride (OXYBUTYNIN CHLORIDE) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: transdermal. Current US regulatory status: approved.
What is the brand name for oxybutynin chloride?
OXYBUTYNIN CHLORIDE is a marketed brand name for oxybutynin chloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of oxybutynin chloride?
oxybutynin chloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.